Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023 08:00 ET
|
Freeline Therapeutics Holdings plc
LONDON, April 12, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its Chief Executive Officer Michael Parini will present at the 22nd Annual Needham...
Freeline Reports Full Year 2022 Financial Results and Provides Corporate Update
April 04, 2023 07:00 ET
|
Freeline Therapeutics Holdings plc
Prioritizing development of FLT201, a potential first- and best-in-class gene therapy for most common type of Gaucher disease Initial clinical data on FLT201 expected in Q3 2023 Restructuring...
Freeline Therapeutics to Host Full Year 2022 Financial Results Call
March 28, 2023 07:00 ET
|
Freeline Therapeutics Holdings plc
LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, April 4,...
Freeline Reports January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2023 16:30 ET
|
Freeline Therapeutics Holdings plc
LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on January 31, 2023, the Company granted two newly hired employees non-statutory...
Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy
January 19, 2023 08:01 ET
|
Freeline Therapeutics Holdings plc
Data show increased enzyme activity and reduction of harmful substrate, an established biomarker of efficacy in Fabry disease, in key tissues and organs FLT190 currently being investigated in...
Freeline Receives Approval to Transfer to Nasdaq Capital Market
November 29, 2022 16:01 ET
|
Freeline Therapeutics Holdings plc
LONDON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that it received approval from the Nasdaq Stock Market LLC...
Freeline Reports Third Quarter 2022 Financial Results and Corporate Update
November 15, 2022 07:00 ET
|
Freeline Therapeutics Holdings plc
Entered into definitive agreement to sell CMC-focused German subsidiary and related IP for $25 million, while retaining rights to AAVS3 capsid and maintaining access to capabilities and technologies ...
Freeline to Present at the Stifel Healthcare Conference
November 09, 2022 07:00 ET
|
Freeline Therapeutics Holdings plc
LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the...
Freeline Reports October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2022 16:01 ET
|
Freeline Therapeutics Holdings plc
LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on October 31, 2022, the Company granted three newly hired employees non-statutory...
Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2022 17:30 ET
|
Freeline Therapeutics Holdings plc
LONDON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on August 31, 2022, the Company granted two newly hired employees non-statutory...